PTEN mRNA Nanoparticle Delivery for Tumor Suppression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Restoring tumor suppressor function in cancer cells is challenging due to inefficient delivery, poor transfection efficacy, and potential insertional mutagenesis, especially in metastatic settings where tumor burden is widespread, and existing mRNA delivery methods face issues with size, charge, degradation, and suboptimal protein translation.

Innovation Solution

A lipid-polymer hybrid nanoparticle platform is used for systemic delivery of modified PTEN mRNA, which encodes the Phosphatase and tensin homolog protein, utilizing cationic lipid G0-C14 and PLGA, with modifications such as ARCA capping, enzymatic polyadenylation, and nucleotide substitutions to enhance stability and delivery efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional DNA-based gene therapy is used to restore tumor suppressor function, then genetic integration is achieved, but delivery efficiency is poor and insertional mutagenesis occurs

Engineering Contradiction:

Improvetumor suppressor restorationVSAvoiddelivery efficiency

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent replaces DNA-based genetic integration with mRNA-based transient expression. Instead of delivering DNA that must integrate into the genome (risking insertional mutagenesis), the invention delivers mRNA that provides temporary protein expression without genomic integration, thereby maintaining reliability while improving delivery efficiency and safety.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the fundamental parameter of the therapeutic agent from DNA to mRNA. This parameter change allows the therapy to avoid genomic integration requirements, eliminating insertional mutagenesis risks while enabling more efficient delivery through nanoparticle systems that can protect and transport mRNA without requiring nuclear entry or integration.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If mRNA is delivered using conventional methods, then protein expression is achieved, but the mRNA is degraded and transfection efficacy is poor

Engineering Contradiction:

Improveprotein expressionVSAvoidmRNA stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent introduces nanoparticle carriers (lipid nanoparticles, polymeric nanoparticles, or exosomes) as intermediary vehicles to deliver mRNA to tumor cells. These nanoparticles protect the fragile mRNA from degradation in the extracellular environment and facilitate its entry into target cells, thereby improving both mRNA stability and transfection efficacy simultaneously.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs composite nanoparticle systems combining lipids, polymers, or other materials with mRNA. These composite structures provide protective shells that shield mRNA from nucleases, improve cellular uptake, and control release, thereby enhancing both the stability of the mRNA composition and the efficacy of transfection.

Inventive Principle:

Principle #40Composite materials

3Adaptability or versatility

If systemic delivery is used to reach widespread metastatic tumors, then tumor burden is addressed, but toxicity increases and delivery precision decreases

Engineering Contradiction:

Improvemetastatic tumor coverageVSAvoidtoxicity

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs nanoparticles functionalized with tumor-targeting ligands (such as antibodies, peptides, or aptamers) that specifically bind to receptors overexpressed on tumor cells. This localizes the mRNA delivery to the tumor site, allowing systemic administration to reach metastatic burdens while minimizing off-target toxicity through selective accumulation and internalization at the tumor location.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach achieves effective intravenous delivery and restoration of PTEN protein function, inhibiting tumor growth and inducing apoptosis in both primary and advanced tumors with minimal toxicity, overcoming previous limitations in mRNA delivery and transfection efficiency.

Implementation Method 1

A lipid-polymer hybrid nanoparticle platform is used for systemic delivery of modified PTEN mRNA

Methodology Applied

Scientific EffectNanoparticle delivery:

Implementation Method 2

utilizing cationic lipid G0-C14 and PLGA

Methodology Applied

Scientific EffectLipid-mRNA complexation:

Implementation Method 3

with modifications such as ARCA capping, enzymatic polyadenylation, and nucleotide substitutions to enhance stability and delivery efficacy

Methodology Applied

Scientific EffectARCA capping:

Implementation Method 4

with modifications such as ARCA capping, enzymatic polyadenylation, and nucleotide substitutions

Methodology Applied

Scientific EffectEnzymatic polyadenylation: Enzyme

Implementation Method 5

This approach achieves effective intravenous delivery and restoration of PTEN protein function, inhibiting tumor growth and inducing apoptosis in both primary and advanced tumors

Methodology Applied

Scientific EffectPTEN-mediated apoptosis induction:

Data Source

PatentUS11471515B2Restoration of tumor suppression using MRNA-based delivery system

Publication Date: 2022.10.18 CHILDRENS MEDICAL CENT CORP

AI summary

Compositions and methods for treating cancer that include administering a therapeutically effective amount of a tumor suppressor mRNA complexed with a delivery vehicle as described herein, e.g., a nanoparticle.